These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 11509060

  • 1. Risk of cardiovascular events associated with selective COX-2 inhibitors.
    Mukherjee D, Nissen SE, Topol EJ.
    JAMA; ; 286(8):954-9. PubMed ID: 11509060
    [Abstract] [Full Text] [Related]

  • 2. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC.
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [Abstract] [Full Text] [Related]

  • 3. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
    Howes LG, Krum H.
    Drug Saf; 2002; 25(12):829-35. PubMed ID: 12241124
    [Abstract] [Full Text] [Related]

  • 4. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA, Weir MR.
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 6. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C, Wagner S.
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [Abstract] [Full Text] [Related]

  • 7. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM.
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [Abstract] [Full Text] [Related]

  • 8. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL.
    Gen Dent; 2000 Sep; 48(1):16-20. PubMed ID: 11199547
    [No Abstract] [Full Text] [Related]

  • 9. The coxibs, selective inhibitors of cyclooxygenase-2.
    FitzGerald GA, Patrono C.
    N Engl J Med; 2001 Aug 09; 345(6):433-42. PubMed ID: 11496855
    [No Abstract] [Full Text] [Related]

  • 10. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA, Hersh EV.
    J Am Dent Assoc; 2001 Apr 09; 132(4):451-6. PubMed ID: 11315375
    [Abstract] [Full Text] [Related]

  • 11. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 09; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 12. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM, Targownik L, Dulai GS, Gralnek IM.
    Ann Intern Med; 2003 May 20; 138(10):795-806. PubMed ID: 12755551
    [Abstract] [Full Text] [Related]

  • 13. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A.
    Rev Med Brux; 2001 Sep 20; 22(4):A377-80. PubMed ID: 11680204
    [Abstract] [Full Text] [Related]

  • 14. COX-2 inhibitors. Magic bullets or merely mortal?
    Harv Health Lett; 2000 Feb 20; 25(4):4. PubMed ID: 10637015
    [No Abstract] [Full Text] [Related]

  • 15. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
    Mukherjee D.
    Biochem Pharmacol; 2002 Mar 01; 63(5):817-21. PubMed ID: 11911832
    [Abstract] [Full Text] [Related]

  • 16. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 17. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.
    Pharmacoepidemiol Drug Saf; 2003 May 04; 12(1):67-70. PubMed ID: 12616850
    [No Abstract] [Full Text] [Related]

  • 18. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
    Graham GG, Graham RI, Day RO.
    Curr Pharm Des; 2002 May 04; 8(12):1063-75. PubMed ID: 11945151
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular events and COX-2 inhibitors.
    Fleming M.
    JAMA; 2001 Dec 12; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract] [Full Text] [Related]

  • 20. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 12; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.